Navigation Links
Growth Achieved in Spherix's Health Sciences Consulting Business

Phase 3 Clinical Trial on Track, Market Research Contracts Signed

BELTSVILLE, Md., Nov. 29 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has recently signed contracts to provide technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies. Spherix's Health Sciences Consulting Division provides scientific and strategic support for suppliers, manufacturers, distributors, and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.

"I am very pleased with the progress made in our Health Sciences Division," said Claire Kruger, CEO and Director of Health Sciences of Spherix. "Revenues earned through these efforts will add to our substantial cash reserve, and will be very useful moving forward."

The Company further reported that its Phase 3 clinical trial of Naturlose(R) as a treatment for Type 2 diabetes is progressing on schedule. Since moving the entire study to the United States, patient recruitment has increased and, logistically, everything is moving ahead much more efficiently. The protocol for the Company's dose ranging study has been finalized and is scheduled to begin later this year. An additional study to determine if Naturlose will work with only one dose per day is being finalized, and it is hoped that this study will begin early next year. Results from a recent trial evaluating efficacy of tagatose in toothpaste that was conducted at the University of Maryland did not show significant activity; further trials for this endpoint are being halted to focus on the diabetes market.

The diabetes drug market is now changing rapidly due to major product withdrawals. In the next strategic step forward in an effort to commercialize Naturlose as a drug to treat diabetes, contracts have been signed with two pharmaceutical market research firms to analyze the current market for Type 2 diabetes drugs and help to position Naturlose within that product space. In addition, primary market research will be conducted under these contracts with physicians and patients to determine the impact of new formulations and dosing regimens, and distributors will be surveyed to package the drug in the optimal form.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is

SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
2. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
3. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
4. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
5. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)... Nov. 25, 2015 Endo International plc (NASDAQ: ... Silva , President and CEO, will discuss corporate updates at ... New York on Wednesday, December 2, ... Click on Investor Relations, and then the link to the ... presentation,s start time to visit the site and download any ...
(Date:11/25/2015)... November 25, 2015 Asia ... to which BioLight and the New Investors will make ... ("IOPtima") via a private placement. The financing will help ... IOPtimate™ system used in the treatment of glaucoma, as ... for the IOPtimate™ system with the U.S. Food and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for ... The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 ...
(Date:11/25/2015)... ... 25, 2015 , ... An unlikely combination of recycled plastic ... for homeless people to have a more dignified and comfortable night’s sleep. , ... are repurposing plastic bags into sleeping mats for the homeless. The project, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
Breaking Medicine News(10 mins):